Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845494 | 0.92 | CYP11B1 (0.46) | POLBSMN1; SMN2MAPTCYP11B1CYP11B2 | |
| SCHEMBL6654310 | 0.78 | CYP11B1 (0.45) | MAPTCYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL6661142 | 0.74 | MAPT (0.39) | SMN1; SMN2MAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL6656515 | 0.73 | CYP17A1 (0.47) | CYP17A1CYP1A2ATM | |
| SCHEMBL6659082 | 0.73 | CYP19A1 (0.47) | MAPTCYP19A1 | |
| SCHEMBL6845462 | 0.73 | MAPT (0.49) | MAPTCYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL6653590 | 0.73 | CYP11B2 (0.49) | MAPTCYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL6660298 | 0.72 | CYP11B2 (0.55) | MAPTCYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL7104139 | 0.72 | CYP11B1 (0.44) | MAPTCYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL6840679 | 0.72 | CYP11B1 (0.52) | MAPTCYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | POLB 2154/4885SMN1; SMN2 4413/4885MAPT 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.